Jump to content

Recommended Posts

Posted

A new drug being developed by Sanofi-Synthelabo called rimonabant works by blocking the same receptors in the brain that are activated by cannabinoids when you smoking pot. It was shown to be effective in smoking cessation and in weight loss, especially in the waist, or so-called "visceral fat". This is going to be a gold mine for Sanofi. Now is the time to buy some stock in the company. This is going to be the greatest thing since sliced bread.

  • Replies 10
  • Created
  • Last Reply

Top Posters In This Topic

Posted

This isn't insider information. The payoff, if there is one, would only come in about two years when the final results of the phase III clinical trials are made public. So here's my take. The phase II trials are large enough to show significant efficacy. The phase III trials will reveal if there are any relatively rare side effects. If it looks good, I'd say this is a drug worth $2-4 billion a year.

  • 8 months later...
Posted

In 6 months time side effects will be shown to include things like constant diahhorea, brain tumors or suicide and then where will all you speculative stock buyers be then?

Posted

and like those or worse side-effects would stop the lose-weight-without-effort types. Paxil has all those and more, AND no clinical evidence of its efficacy; they seem to be doing ok.

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.




×
×
  • Create New...